Guy Krippner
Director/Board Member at Cardiora Pty Ltd.
Guy Krippner active positions
| Companies | Position | Start | End |
|---|---|---|---|
Cardiora Pty Ltd.
 Cardiora Pty Ltd. Investment Trusts/Mutual FundsMiscellaneous Cardiora Pty Ltd. functions as a clinical stage pharmaceutical company. It develops CRD-102, an oral medicine for heart failure. The company was founded by David Kaye in 2015 and is headquartered in Melbourne, Australia. | Director/Board Member | - | - |
Career history of Guy Krippner
Former positions of Guy Krippner
| Companies | Position | Start | End |
|---|---|---|---|
Verva Pharmaceuticals Ltd.
 Verva Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Verva Pharmaceuticals Ltd. developed therapies to treat diabetes. Its products include insulin sensitizers, insulin secretagogues, fat formation inhibitors for the prevention, treament of obesity, drug-induced weight gain and insulin secretion modulators. The company was founded in 1996 and was headquartered in Geelong, Australia. | Corporate Officer/Principal | - | - |
Training of Guy Krippner
| University of Adelaide | Doctorate Degree |
Statistics
International
| Australia | 4 |
Operational
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Sectoral
| Health Technology | 2 |
| Consumer Services | 2 |
| Miscellaneous | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Verva Pharmaceuticals Ltd.
Verva Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Verva Pharmaceuticals Ltd. developed therapies to treat diabetes. Its products include insulin sensitizers, insulin secretagogues, fat formation inhibitors for the prevention, treament of obesity, drug-induced weight gain and insulin secretion modulators. The company was founded in 1996 and was headquartered in Geelong, Australia. | Health Technology |
Cardiora Pty Ltd.
Cardiora Pty Ltd. Investment Trusts/Mutual FundsMiscellaneous Cardiora Pty Ltd. functions as a clinical stage pharmaceutical company. It develops CRD-102, an oral medicine for heart failure. The company was founded by David Kaye in 2015 and is headquartered in Melbourne, Australia. | Miscellaneous |
- Stock Market
- Insiders
- Guy Krippner
- Experience
